| scholarly article | Q13442814 |
| P50 | author | Massimo Valoti | Q68083259 |
| Daniele Bolognini | Q93139102 | ||
| Roger Pertwee | Q29643420 | ||
| Livio Luongo | Q30388998 | ||
| P2093 | author name string | Andrea Tafi | |
| Vincenzo Di Marzo | |||
| Alessia Ligresti | |||
| Ruin Moaddel | |||
| Federico Corelli | |||
| Sabatino Maione | |||
| Claudia Mugnaini | |||
| Serena Pasquini | |||
| Luca Bellucci | |||
| Francesca Guida | |||
| Maria Grazia Cascio | |||
| Stefania Dragoni | |||
| Valentina Pedani | |||
| Maria De Chiaro | |||
| Avraham Rosenberg | |||
| Stefania Nocerino | |||
| P2860 | cites work | A medicinal chemist's guide to molecular interactions | Q37719514 |
| Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. | Q39827504 | ||
| Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors | Q39956082 | ||
| Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice | Q42731656 | ||
| 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. | Q42849777 | ||
| Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. | Q42951315 | ||
| In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists | Q43229565 | ||
| The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats | Q43674677 | ||
| Synthesis of steroidal diacyl hydrazines and their 1,3,4-oxadiazole derivatives | Q43984071 | ||
| Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity | Q46293357 | ||
| Sterically biased 3,3-sigmatropic rearrangement of chiral allylic azides: application to the total syntheses of alkaloids | Q46471928 | ||
| MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist | Q46775772 | ||
| A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo | Q46781687 | ||
| The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and cannabinoids | Q46925045 | ||
| General atomic and molecular electronic structure system | Q56017006 | ||
| A suitable 1,2,4-oxadiazoles synthesis by microwave irradiation | Q57589002 | ||
| A new energy decomposition scheme for molecular interactions within the Hartree-Fock approximation | Q60019341 | ||
| Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case | Q60657587 | ||
| Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles | Q67231665 | ||
| Pair interaction energy decomposition analysis | Q79364310 | ||
| Cannabinoids and multiple sclerosis | Q81478365 | ||
| Rationale and benefit of using high throughput solubility screens in drug discovery | Q88186347 | ||
| CB2 receptor-mediated migration of immune cells: it can go either way | Q24643591 | ||
| The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset | Q24650098 | ||
| Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630 | Q24672356 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ | Q28298445 | ||
| In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor | Q31842135 | ||
| Biological assay challenges from compound solubility: strategies for bioassay optimization | Q33240945 | ||
| Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists | Q33357643 | ||
| Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data | Q33438089 | ||
| The formalin test: scoring properties of the first and second phases of the pain response in rats. | Q34058687 | ||
| The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice | Q34098266 | ||
| Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain | Q34118976 | ||
| Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands | Q34131883 | ||
| Synopsis of some recent tactical application of bioisosteres in drug design | Q34171394 | ||
| Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. | Q34328742 | ||
| SR141716A, a potent and selective antagonist of the brain cannabinoid receptor | Q34332716 | ||
| SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. | Q34455195 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists | Q34618512 | ||
| Development and characterization of immobilized cannabinoid receptor (CB1/CB2) open tubular column for on-line screening | Q34647921 | ||
| Cannabinoid receptors and their ligands | Q34673022 | ||
| Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo | Q34804266 | ||
| Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. | Q35620660 | ||
| Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery | Q35866108 | ||
| AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. | Q36176518 | ||
| Cannabinoid receptors in acute and chronic complications of atherosclerosis. | Q36416368 | ||
| Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning | Q36416372 | ||
| Role of pharmacologically active metabolites in drug discovery and development | Q36419988 | ||
| Pharmacological actions of cannabinoids. | Q36441175 | ||
| High throughput solubility measurement in drug discovery and development | Q36866852 | ||
| Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 | ||
| Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain | Q36997712 | ||
| Cannabinoids for cancer treatment: progress and promise | Q37058660 | ||
| Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. | Q37132540 | ||
| Emerging strategies for exploiting cannabinoid receptor agonists as medicines | Q37230665 | ||
| Targeting CB2 receptors and the endocannabinoid system for the treatment of pain | Q37371095 | ||
| Antagonists of the P2X(7) receptor. From lead identification to drug development. | Q37384921 | ||
| Cannabinoids in the treatment of cancer | Q37482337 | ||
| Endocannabinoid system modulation in cancer biology and therapy. | Q37532978 | ||
| Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands | Q37622364 | ||
| P433 | issue | 5 | |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| quinolones | Q426549 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 920-934 | |
| P577 | publication date | 2012-03-02 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach | |
| P478 | volume | 7 |
| Q64100848 | Catalyst-free assembly of giant tris(heteroaryl)methanes: synthesis of novel pharmacophoric triads and model sterically crowded tris(heteroaryl/aryl)methyl cation salts |
| Q28072198 | Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey |
| Q95416436 | Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases |
| Q33671206 | Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor |
| Q64866431 | Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases |
| Q36167110 | Structure-activity relationship studies of QS11, a small molecule Wnt synergistic agonist. |
| Q57990211 | Synthesis of new porphyrin/4-quinolone conjugates and evaluation of their efficiency in the photoinactivation of Staphylococcus aureus |
Search more.